TrialCancer immunology, immunotherapy : CII2010

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.

Masanori Noguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.